What We're Reading: Page 62
Industry reads hand-picked by our editors
Feb 13, 2024
-
The Hill
Federal judge tosses PhRMA lawsuit challenging Medicare drug negotiations
-
Reuters
Exscientia fires CEO after probe over relationship with two employees
-
FirstWord Pharma
Otsuka set for $770 million charge on study failure of Alzheimer’s disease agitation drug
-
Financial Times
Blood protein test offers ‘reliable’ Alzheimer’s warning 15 years early
Feb 12, 2024
Feb 09, 2024
-
Reuters
Astrazeneca says Catalent deal shows need for in-house capacity
-
FirstWord Pharma
Synlogic shutters operations after ending phenylketonuria trial
-
Fierce Biotech
Roche to shrink product development team
Feb 08, 2024
-
Bloomberg
AstraZeneca’s Outlook Disappoints Amid Profit Margin Concern
-
Axios
How a company cut health spending by nearly half
-
The Transmitter
U.S. government requested inquiry into Alzheimer’s scientist over misconduct allegations
-
Wired
A Study at the Center of the Abortion Pill Battle Was Just Retracted
Feb 07, 2024
-
Financial Times
Eli Lilly calls for scrutiny of rival Novo Nordisk’s deal to expand production of weight-loss drug
-
Reuters
US FDA finds control lapses at Catalent plant being sold to Novo
-
Axios
Biden admin pushes pharmacy execs on COVID treatment Paxlovid costs
-
C&EN
Lawmakers introduce bill to fix the Inflation Reduction Act’s ‘small-molecule penalty’
Feb 06, 2024
Feb 05, 2024
-
AP News
As investors pile into psychedelics, idealism gives way to pharma economics
-
Bloomberg
Generic Drugs Made in India Rely Heavily on Chinese-Made Ingredients
-
Axios
Biotech is the new focus in U.S.-China tech rivalry
-
Nature News
Elon Musk’s Neuralink brain chip: what scientists think of first human trial
Previous
